Atara Biotherapeutics Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 12,000 shares of the business’s stock in a transaction dated Wednesday, November 23rd. The stock was sold at an average price of $18.34, for a total value of $220,080.00. Following the sale, the chief executive officer now owns 555,044 shares in the company, valued at $10,179,506.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Atara Biotherapeutics Inc. (NASDAQ:ATRA) opened at 19.80 on Monday. Atara Biotherapeutics Inc. has a 12-month low of $12.45 and a 12-month high of $40.80. The company’s market capitalization is $571.43 million. The firm’s 50 day moving average price is $16.70 and its 200-day moving average price is $19.67.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Friday, November 4th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.10. On average, equities analysts anticipate that Atara Biotherapeutics Inc. will post ($3.05) earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in ATRA. Barclays PLC boosted its stake in Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock valued at $108,000 after buying an additional 4,600 shares during the last quarter. Panagora Asset Management Inc. acquired a new stake in Atara Biotherapeutics during the third quarter valued at $110,000. BlackRock Group LTD boosted its stake in Atara Biotherapeutics by 3.7% in the third quarter. BlackRock Group LTD now owns 5,532 shares of the company’s stock valued at $119,000 after buying an additional 198 shares during the last quarter. BlackRock Inc. boosted its stake in Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock valued at $137,000 after buying an additional 5,019 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock valued at $148,000 after buying an additional 6,467 shares during the last quarter. 77.18% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have recently weighed in on the company. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 19th. Citigroup Inc. boosted their price target on Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a report on Friday, August 19th. Jefferies Group restated a “buy” rating and set a $25.00 price target on shares of Atara Biotherapeutics in a report on Tuesday, August 9th. Goldman Sachs Group Inc. cut Atara Biotherapeutics from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $23.00 to $16.00 in a report on Thursday, September 15th. Finally, Canaccord Genuity set a $47.00 price target on Atara Biotherapeutics and gave the stock a “buy” rating in a report on Sunday, November 6th. Three equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. Atara Biotherapeutics currently has an average rating of “Hold” and an average price target of $25.86.
Atara Biotherapeutics Company Profile